Biocon Q1 Results | Net profit tanks 95% to ₹31 crore, misses estimates

Biotechnology firm Biocon Ltd on Thursday (August 7) reported a steep 95.2% year-on-year (YoY) decline in consolidated net profit at ₹31.4 crore for the quarter ended June 30, 2025, compared to ₹659.7 crore in the corresponding period last year. The reported profit also came in significantly below CNBC-TV18’s estimate of ₹102.3 crore.Revenue from operations, however, grew 1 4.8% YoY to ₹3,942 crore, against ₹3,433 crore in the year-ago period. This figure too fell short of the CNBC-TV18 poll, which had pegged revenue at ₹4,096.2 crore.

On the operational front, EBITDA rose 20.7% YoY to ₹749 crore, up from ₹620.4 crore in Q1FY25. The operating margin stood at 19%, a modest improvement over 18.1% last year but below the CNBC-TV18 estimate of 20.8%.

Biocon Group’s Chairperson Kiran Mazumdar-Shaw remained optimistic, citing recent milestones including the launch of Yesafili in Canada.
“Key developments this quarter include the launch of Yesafili in Canada, our tenth biosimilar globally, and USFDA approval for Insulin Aspart, our second interchangeable biosimilar Insulin, further deepening our presence in the U.S. insulin market,” Shaw added.

The company says it is well-positioned to drive long-term value creation in FY26 and beyond, with strong progress across all its businesses and increased capacity from US acquisitions by Syngene and Biocon Generics.

Biocon said it continued to strengthen its presence in Europe with the launch of Yesintek in key markets. Its biosimilars, Ogivri and Abevmy, reported market shares of 21% and 15%, respectively.

In the biosimilars segment, revenue from operations rose 18% year-on-year to ₹2,458 crore in Q1FY26, supported by strong global demand. This translated into an EBITDA of ₹645 crore, a 36% increase on a like-for-like basis.

The company also completed its first equity fundraise since its 2004 IPO, raising ₹4,500 crore via a Qualified Institutions Placement (QIP) in June 2025. The issue drew strong interest from both domestic and international investors. The funds will be used to increase Biocon’s stake in Biocon Biologics and facilitate an exit for its private equity investors.

Separately, Biocon’s board cleared an investment of up to ₹1.4 crore in Pro-zeal Green Power Sixteen Pvt Ltd, involving a 26% equity stake and convertible debentures. The deal is aimed at sourcing solar energy from a captive plant, as the company looks to reduce its carbon footprint.

Shares of Biocon Ltd ended higher on Thursday by 1.39% at ₹365.40 on NSE.

Also Read: NLC India Q1 net profit surges 43% to ₹798 crore; approves ₹5,228 crore asset transfer to renewable arm